

National Board of Examinations

Question Paper Name :	DrNB Medical Oncology Paper2
Subject Name :	DrNB Medical Oncology Paper2
Creation Date :	2025-01-19 09:52:30
Duration :	180
Total Marks :	100
Display Marks:	No
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB Medical Oncology Paper2

Group Number :	1
Group Id :	3271872845
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100

DrNB Medical Oncology Paper2

Section Id :	3271872848
Section Number :	1
Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions :	10
Number of Questions to be attempted :	10
Section Marks :	100
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271872852
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718729734 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) CML & pregnancy. [5]
- b) Outline management of APML. [5]

Question Number : 2 Question Id : 32718729736 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Management of highly emetogenic CINV (chemo induced nausea vomiting). [5]
- b) Netupitant. [3]
- c) Olanzapine (low dose and standard dose). [2]

Question Number : 3 Question Id : 32718729737 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Role of genetic testing in carcinoma of prostate. [5]
- b) Management of castrate resistant prostate cancer (CRPC). [5]

Question Number : 4 Question Id : 32718729738 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Targeted treatment in metastatic carcinoma of stomach. [5]
- b) Management of borderline resectable carcinoma pancreas. [5]

Question Number : 5 Question Id : 32718729739 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Next-generation sequencing (NGS) in sarcoma. [5]
- b) PRRT in NET. [5]

Question Number : 6 Question Id : 32718729740 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Risk factors for hepatocellular carcinoma (HCC). [5]
- b) Role of immunotherapy in the management of HCC. [5]

Question Number : 7 Question Id : 32718729741 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) IRSS staging of retinoblastoma. [5]
- b) Maintenance therapy in RMS. [5]

Question Number : 8 Question Id : 32718729742 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Management of BRCA associated locally advanced triple negative breast cancer(TNBC). [5]
- b) OlympiAD trial. [5]

Question Number : 9 Question Id : 32718729743 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Interim PET in Hodgkin's Lymphoma (HL). [5]
- b) De-escalation & escalation therapies in early & advanced HL. [5]

Question Number : 10 Question Id : 32718734986 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Accelerated partial breast irradiation. [5]
- b) Ga68- DOTANOC PET scan. [5]